Product Description
Mechanisms of Action: ADRA Antagonist, ADRB Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Argentina | Brazil | Chile | Egypt | India | Indonesia | Ireland | Italy | New Zealand | Peru | Philippines | Portugal | Taiwan | Ukraine | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: University of New Mexico
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Multiple Sclerosis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03752307 |
NCT03752307 | P2 |
Completed |
Multiple Sclerosis |
2023-07-06 |
2024-02-07 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |